Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
Interferon-ribavirin-associated ischemic colitis
Ezetimibe-associated thrombocytopenia;
Ventricular arrhymia during sodium bicarbonate infusion;
Baboon syndrome induced by cetuximab;
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
Pluristem to be Featured on RedChip's Real Radio(TM) Show Broadcast
Pluristem to be Featured on RedChip's Real Radio(TM) Show Broadcast
The 10th Annual C21 BioVentures Presenter Profiles
Pluristem Announces Removal of Restrictive Legends on Shares of Restricted Common Stock According to May 2007
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive
Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119,
Medarex Announces Initiation Of Phase 2 Clinical Trials For The Treatment Of Ulcerative Colitis And Rheumatoid
JournalScan
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Programs; Announces First Quarter 2008 Fin
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid
